Leading Regional US Airline Adopts Implant Sciences' QS-B220 Explosives Trace Detector for Air Cargo Screening
Implant Sciences Corporation (OTCQB:IMSC), a high technology supplier of systems and sensors for homeland security and defense markets, announced today that it has sold its QS-B220 desktop explosives trace detector to a leading regional US airline with growing air cargo revenues. The seven units will be deployed across five locations in the airline's network.
"The customer was impressed with the QS-B220's ease of use, non-radioactive source, push-button maintenance, and its low cost of ownership," stated Implant Sciences' Vice President of Sales and Marketing, Dr. Darryl Jones. "Buyer after buyer is telling us that the value proposition offered by Implant Sciences is far superior to anything else they've seen."
Global Aerostat Systems Market 2015-2019
"As a leading airline that also conducts its own baggage screening, the purchase decision makers at this airline are extremely experienced and knowledgeable about air cargo screening. It was a pleasure working with them, and we look forward to a long-term customer relationship with them," stated Glenn D. Bolduc, President and CEO of Implant Sciences.
About the QS-B220 Desktop Explosives Trace Detector
The QS-B220 uses Ion Mobility Spectrometry (IMS) to rapidly detect and identify trace amounts of a wide variety of military, commercial, and homemade explosives as well as drugs. With significantly lower maintenance requirements than competing systems, the QS-B220 can be deployed for a much lower total cost of ownership than competing products. Featuring a radioactive material-free design, push-button maintenance and diagnostics, and a patented inCal™ internal automatic calibration system, the QS-B220 brings new levels of performance and convenience to desktop trace detection users with unsurpassed ease of use.
Your company’s press release on ASDNews and to thousands of other journalists and editors? Use our ASDWire press release distribution service.
Source : Implant Sciences Corporation
Jun 2 - 3, 2016 - Washington, United States